First test of new precision drug targets Cancer's genetic weakness
Disease control
Recruiting now
This is the first study in people for a new drug called OKI-219, designed to target a specific genetic mutation (PI3KαH1047R) found in some advanced cancers. The main goals are to find a safe dose and see how the body handles the drug, both alone and combined with other cancer tr…
Phase: PHASE1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC